Cargando…
Current Control and Future Risk in Asthma Management
Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronc...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178819/ https://www.ncbi.nlm.nih.gov/pubmed/21966601 http://dx.doi.org/10.4168/aair.2011.3.4.217 |
_version_ | 1782212442740228096 |
---|---|
author | Sims, Erika J Price, David Haughney, John Ryan, Dermot Thomas, Mike |
author_facet | Sims, Erika J Price, David Haughney, John Ryan, Dermot Thomas, Mike |
author_sort | Sims, Erika J |
collection | PubMed |
description | Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma. |
format | Online Article Text |
id | pubmed-3178819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease |
record_format | MEDLINE/PubMed |
spelling | pubmed-31788192011-10-01 Current Control and Future Risk in Asthma Management Sims, Erika J Price, David Haughney, John Ryan, Dermot Thomas, Mike Allergy Asthma Immunol Res Review Despite international and national guidelines, poor asthma control remains an issue. Asthma exacerbations are costly to both the individual, and the healthcare provider. Improvements in our understanding of the therapeutic benefit of asthma therapies suggest that, in general, while long-acting bronchodilator therapy improves asthma symptoms, the anti-inflammatory activity of inhaled corticosteroids reduces acute asthma exacerbations. Studies have explored factors which could be predictive of exacerbations. A history of previous exacerbations, poor asthma control, poor inhaler technique, a history of lower respiratory tract infections, poor adherence to medication, the presence of allergic rhinitis, gastro-oesophageal reflux disease, psychological dysfunction, smoking and obesity have all been implicated as having a predictive role in the future risk of asthma exacerbation. Here we review the current literature and discuss this in the context of primary care management of asthma. The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease 2011-10 2011-09-21 /pmc/articles/PMC3178819/ /pubmed/21966601 http://dx.doi.org/10.4168/aair.2011.3.4.217 Text en Copyright © 2011 The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Sims, Erika J Price, David Haughney, John Ryan, Dermot Thomas, Mike Current Control and Future Risk in Asthma Management |
title | Current Control and Future Risk in Asthma Management |
title_full | Current Control and Future Risk in Asthma Management |
title_fullStr | Current Control and Future Risk in Asthma Management |
title_full_unstemmed | Current Control and Future Risk in Asthma Management |
title_short | Current Control and Future Risk in Asthma Management |
title_sort | current control and future risk in asthma management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178819/ https://www.ncbi.nlm.nih.gov/pubmed/21966601 http://dx.doi.org/10.4168/aair.2011.3.4.217 |
work_keys_str_mv | AT simserikaj currentcontrolandfutureriskinasthmamanagement AT pricedavid currentcontrolandfutureriskinasthmamanagement AT haughneyjohn currentcontrolandfutureriskinasthmamanagement AT ryandermot currentcontrolandfutureriskinasthmamanagement AT thomasmike currentcontrolandfutureriskinasthmamanagement |